Table 4.
Reported results of tyrosine kinase and immune checkpoint inhibitors in ATC.
| Authors | Year | TKI or ICI | No. of ATC Patients | Response | Median OS and PFS since TKI/IMT |
|---|---|---|---|---|---|
| Sherman et al. [37] | 2019 | Durvalumab + tremelimumab (+SBRT) | 12 | ORR: 0 (0%) SD: 1 (8%) |
OS: 14.5 weeks |
| Harris et al. [38] | 2019 | Everolimus | 5 | PR: 1 (20%), SD: 2 (40%); PD: 1 (20%) | OS: 7.4 mo |
| Iyer et al. [20] | 2018 | Dabrafenib + trametinib Lenvatinib |
6 10 |
PR: 3 (50%); SD: 2(33%) PR: 3 (30%); SD: 4 (40%) |
OS: 9.3 mo; PFS: 5.2 mo OS: 3.9 mo; PFS: 2.6 mo |
| Iyer et al. [35] | 2018 | Pembrolizumab (added to TKI) | 12 | PR: 5 (42%); SD: 4 (33%); PD: 3 (25%) | OS: 6.94 mo PFS: 2.96 mo |
| Wirth et al. [39] | 2018 | Spartalizumab | 30 | ORR: 5–6 (17–20%), depending on the criteria | |
| Subbiah et al. [31] | 2017 | Dabrafenib † trametinib | 16 | ORR: 69% | |
| Tahara et al. [30] | 2017 | Lenvatinib | 17 | PR: 4 (24%); SD: 12 (71%); PD: 1 (6%) | OS: 20.6 mo PFS: 7.4 mo |
| Ito et al. [40] | 2017 | Sorafenib | 10 | CR: 0 (0%); PR: 0 (0%); SD: 4 (40%) | OS: 5 mo PFS: 2.8 mo |
| Ravaud et al. [41] | 2017 | Sunitinib | 4 | OS: 5.7 mo PFS: 9.8 mo (2 pts) |
|
| Iniguez-Ariza [42] | 2017 | Lenvatinib | 3 | PR: 0 (0%); SD: 1 (33%) | OS: 2–7 mo |
| Kollipara et al. [36] | 2017 | Vemurafenib † nivolumab | 1 | CR | |
| Hyman et al. [43] | 2016 | Vemurafenib | 7 | CR: 1 (14%); PR: 1 (14%); SD: 0 (0%); PD: 4 (57%) | |
| Godbert et al. [44] | 2015 | Crizotinib | 1 | Response >90% | |
| Marten et al. [45] | 2015 | Vemurafenib | 1 | PD after 2 mo | |
| Wagle et al. [46] | 2014 | Everolimus | 1 | 18 mo | |
| Lim et al. [47] | 2013 | Everolimus | 6 | PR: 1 (17%) | |
| Savvides et al. [48] | 2013 | Sorafenib | 20 | PR: 2 (10%); SD: 5 (25%) | OS: 3.9 mo PFS: 1.9 mo |
| Rosove et al. [49] | 2013 | Vemurafenib | 1 | PR | |
| Bible et al. [50] | 2012 | Pazopanib | 16 | PD: 16 (100%) | OS: 111 days PFS: 62 days |
| Ha et al. [51] | 2010 | Imatinib | 4 | PR: 2 (25%); SD: 4 (50%) | 6 mo-OS: 46% 6 mo-PFS: 27% |
| Pennell et al. [52] | 2008 | Gefitinib | 5 | PR: 0 (0%) |
CR, complete response; ICI, immune checkpoint inhibitors; mo, months; ORR, overall response ratio; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; SBRT, stereotactic body radiotherapy; TKI, tyrosine kinase inhibitors.